Pediatric non-cirrhotic portal hypertension: Endoscopic outcome and perspectives from developing nations

Table 2 Clinical characteristics and outcome of congenital hepatic fibrosis in pediatric studies

Parameters		Rawat et al[106] (n = 40)	Poddar et al[105] (n = 15)	Parkash et al[111] (n = 25)	Luoto et al[112] (n = 27)
Mean or median age		1.3 yr	8 yr (10 mo-14 yr)	8.5 ± 2.7 yr	2.7 (0-13) yr
Associations
	Caroli’s syndrome	52.50%	9%	8%	11%
	Renal	92.50%	81.80%	24%	100%
	CHF	47.50%	54.50%	92%	37%
Presentations
	Variceal bleeding	27%	54.50%	60%	15%
	Cholangitis	25%	9%	0%	7.40%
	Recurrent cholangitis	7.50%	9%	0%	3.70%
	Decompensation	5%	18.20%	0%	19%
	Endotherapy	27%	100%	60%	30%
	Shunt surgery	0%	9%	20%	3.70%
Transplant
	Renal transplant	0%	-	-	41%
	Liver transplant	5%	-	-	3.70%
	Combined liver kidney transplant	45%	-	-	37%
Survival
	Overall survival	90%	100% [41 (1-80) mo]	100%	70% [10.6 (0.6-40) yr]
	Survival post-transplant (follow-up duration)	80% [5 (1.2-9)] yr	-	-	73.30%
	Survival non-transplant (follow-up duration)	100% [15 (4.5-19)] yr	-	-	100%

CHF: Congenital hepatic fibrosis.